CellRapeutics™ Synthetic Intramembrane Proteolysis Receptor CAR Construction Service

Background

Synthetic Intramembrane Proteolysis Receptor (SNIPR) CARs represent an innovative approach in the field of CAR-T cell therapy, where the activation of T cells is controlled through proteolytic cleavage mechanisms. This technology integrates ligand binding with subsequent proteolytic cleavage to release intracellular signaling domains, which then modulate gene expression or other intracellular functions.

Fig.1 Construction of SNIPR.¹

CellRapeutics™ Synthetic Intramembrane Proteolysis Receptor CAR Construction Service at Creative Biolabs

Creative Biolabs provides the necessary expertise and infrastructure to support the successful development and implementation of SNIPR CAR. We ensure high-quality, targeted, and innovative solutions for advanced CAR-T cell therapies tailored to specific research or treatment needs.

• Our SNIPR CAR construction service platform

• The SNIPR CAR construction includes the following features:
  Highly programmable
  Orthogonal signal transduction
  Easy to engineer cells
  Humanization of low immunogenicity

What We Can Offer

Please contact us to set up a private consultation and receive a comprehensive technical proposal.

Related Services

Highlights of our Synthetic Intramembrane Proteolysis Receptor CAR Construction Service

• Enhanced Specificity and Control
  SNIPR CARs allow for highly specific activation of T cells in response to precise proteolytic signals, reducing off-target effects and increasing therapeutic efficacy.
• Modulation of Gene Expression
  By incorporating gene regulatory elements, SIPR CARs can control the expression of therapeutic genes, enabling customized and dynamic responses to the disease environment.
• Safety Profiles
  The additional control mechanisms provided by SIPR CARs help to mitigate risks associated with uncontrolled T cell activation, such as cytokine release syndrome (CRS).
• Versatility
  SNIPR CARs can be adapted to a wide range of diseases by targeting specific proteolytic signals associated with different pathologies.

Note: Due to its relatively large size, SNIPR CAR is not suitable for gene therapy via AAV delivery.

Data Display

The following study has on SNIPR. This study addresses the limitations currently in vivo in predicting the safety of CAR T through PET-compatible SNIPR T cells.

1. Generation of SNIPR T cells		2. In Vivo Assay
Fig.2 Generation of SNIPR T cells.2	Fig.2 is a schematic diagram of SNIPR T cell generation.	Fig.3 In vivo assay.2	Generate a double xenograft mouse model by implanting different cells into soft tissues. SNIPR T cells are then injected into the post-tumor implantation species for PET/CT in small animals.

Applications of Synthetic Intramembrane Proteolysis Receptor CAR

SNIPR CARs offer precise and controlled activation in response to specific proteolytic signals. Their applications span across various fields including cancer, autoimmune diseases, infectious diseases, inflammatory conditions, and fibrotic diseases, providing opportunities for more effective and safer treatments.

Frequently Asked Questions

Q1: When to consider a synthetic intramembrane proteolysis receptor CAR construction?

A1: Synthetic Intramembrane Proteolysis Receptors are an advanced type of engineered receptors designed to improve CAR-T cell functionality and control. This technology can be advantageous in certain contexts:

• Targeting tumor microenvironments with soluble factors;
• Precision activation and control of CAR-T cells;
• Dual-signal requirements for activation;
• Regulating T cell functions beyond cytotoxicity;
• Addressing heterogeneous tumor environments.

As a qualified service provider for the construction and development of SNIPR CAR, Creative Biolabs is an organization with expertise in CAR-T cell technology, synthetic biology, and molecular biology. You can always get in touch with our scientists for more information about SNIPR CAR.

References

1. Teng, F.; et al. "Programmable synthetic receptors: the next-generation of cell and gene therapies." Sig Transduct Target Ther. (2024).
2. Shin, Jaehoon et al. "Antigen-dependent inducible T-cell reporter system for PET imaging of breast cancer and glioblastoma." Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. 64,1 (2023): 137-144.